Aprio Wealth Management LLC Has $1.88 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Aprio Wealth Management LLC increased its stake in Johnson & Johnson by 40.8% in Q1, bringing its total holdings to $1.88 million.
• UBS Group raised their target price on Johnson & Johnson stock from $180 to $190, while Citigroup also increased their target from $185 to $200, indicating growing analyst confidence.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with a current yield of 2.9% and a payout ratio of 55.61%.

Aprio Wealth Management LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 40.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,340 shares of the company's stock after acquiring an additional 3,285 shares during the period. Aprio Wealth Management LLC's holdings in Johnson & Johnson were worth $1,881,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lantz Financial LLC raised its holdings in shares of Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares during the last quarter. Apexium Financial LP increased its position in Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC raised its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the last quarter. State of Wyoming lifted its position in shares of Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock traded down $0.57 on Friday, reaching $178.20. The company had a trading volume of 9,733,095 shares, compared to its average volume of 8,970,201. The company has a 50-day moving average of $168.06 and a 200-day moving average of $160.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market cap of $429.15 billion, a PE ratio of 19.06, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 EPS. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.